Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8692425 | 0.82 | ALDH1A1 (0.35) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL6403682 | 0.79 | ALDH1A1 (0.41) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7640097 | 0.78 | ALDH1A1 (0.33) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL6402618 | 0.75 | TLR8 (0.37) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL6396670 | 0.74 | — | — | |
| SCHEMBL7633778 | 0.74 | PGK1 (0.36) | ALDH1A1NPC1RAB9ALMNAKDM4E | |
| SCHEMBL10719493 | 0.74 | MEN1 (0.44) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL6401579 | 0.73 | TLR8 (0.40) | — | |
| SCHEMBL6403131 | 0.73 | TLR8 (0.40) | — | |
| SCHEMBL6397725 | 0.73 | TLR8 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0356271-B1 | 2,4-Diamino-pyrimidine-3-oxide derivatives and their use in the treatment and the prevention of hair drop | OREAL (FR) | 1995-04-05 | — | — | EP | claimed |
| US-4973474-A | 2,4-diaminopyrimidine 3-oxide derivatives and their use for the treatment and prevention of hair loss | L'OREAL (FR) | 1990-11-27 | — | — | US | claimed |
| JP-2078666-A | — | — | None | — | — | JP | disclosed |
| US-20050049232-A1 | Composition | LINDAU PAR (SE) | 2005-03-03 | — | — | US | disclosed |
| EP-1463483-A1 | NEW COMPOSITION | Ponsus Pharma AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055454-A1 | NEW COMPOSITION | PONSUS PHARMA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| US-4973474-A | 2,4-diaminopyrimidine 3-oxide derivatives and their use for the treatment and prevention of hair loss | L'OREAL (FR) | 1990-11-27 | — | — | US | disclosed |
| JP-H0278666-A | NEW 2,4-DIAMINOPYRIMIDINE 3-OXIDE DERIVATIVE AND COMPOSITION CONTAINING IT | L'OREAL SA | 1990-03-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049232-A1 | Composition | CUTA, LIPG, LIPA | ALDH1A1 1751/4885NPC1 2500/4885RAB9A 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.